HR Execs on the Move

Optinose

www.optinose.com

 
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.optinose.com
  • 1020 Stony Hill Road Suite 300
    Yardley, PA USA 19067
  • Phone: 267.364.3500

Executives

Name Title Contact Details
Krick Neely
Chief Finance Officer Profile
Keith Goldan
Chief Financial Officer Profile
Anthony Krick
Vice President and Chief Accounting Officer Profile
Michele Janis
Vice President of Finance and Acting Chief Financial Officer Profile

Similar Companies

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.

Vilex

Vilex is an innovative manufacturer of orthopaedic internal and external fixation devices, plates, and small joint implants.

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Tahiti Trade Super Nutaceuticals

Tahiti Trade Super Nutaceuticals is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Umoja Biopharma

Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.